Advertisement

Clinical Pharmacokinetics

, Volume 12, Issue 6, pp 379–401 | Cite as

The Relationship Between the Pharmacokinetics and Pharmacodynamic Effects of Oral Hypoglycaemic Drugs

  • Robin E. Ferner
  • Stephen Chaplin
Review Article

Summary

Oral hypoglycaemic drugs have widely differing pharmacokinetic properties. Possible pharmacodynamic benefits include greater efficacy and fewer adverse effects. In general, it has not been possible to demonstrate unequivocal differences in clinical efficacy between the sulphonylureas during long term use, although there are clear differences in potency.

These differences have been emphasised to the extent that the term ‘second-generation’ has been used for the most potent sulphonylureas, but there is little to suggest that potency is of any therapeutic significance. Trials to study differences in efficacy have rarely been of acceptable design. They have often used fixed doses of drugs, begging the question of whether true potency ratios have been established for chronic treatment. They have rarely involved substantial numbers of patients in double-blind crossover studies with a suitable washout period. Trials which show that there is a clear relationship between drug concentrations in blood and drug effects (whether therapeutic effects or adverse effects such as severe hypoglycaemia) are generally lacking.

Qualitative and semiquantitative analysis of adverse effects supports the concept that drugs with a long half-life (e.g. chlorpropamide), renally excreted active metabolites (e.g. acetohexamide) or unusual properties (e.g. glibenclamide, which accumulates progressively in islet tissue) are more likely to cause prolonged hypoglycaemia, which may be fatal. The major adverse effect of treatment with biguanides is lactic acidosis, and this probably occurs more commonly in patients treated with phenformin than those treated with metformin because of pharmacogenetic variation in phenformin metabolism.

The available evidence therefore favours the use of drugs with a short elimination half-life which are extensively metabolised and which have no active metabolites.

Keywords

Clinical Pharmacology Glibenclamide Tolbutamide Gliclazide Glipizide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams WJ, Skinner GS, Bombardt PA, Courtney M, Brewer JE. Determination of glyburide in human serum by liquid chromatography with fluorescence detection. Analytical Chemistry 54: 1287–1291, 1982PubMedCrossRefGoogle Scholar
  2. Adir J, Miller AK, Vestal RE. Effects of total plasma concentration and age on tolbutamide plasma protein binding. Clinical Pharmacology and Therapeutics 31: 488–493, 1982PubMedCrossRefGoogle Scholar
  3. Andrews WJ, Vasques B, Nagulesparan M, Klimes I, Foley J, et al. Insulin therapy in obese non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for 2 weeks after withdrawal. Diabetes 33: 634–642, 1984PubMedCrossRefGoogle Scholar
  4. Antal EJ, Gillespie WR, Phillips JP, Albert KS. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients. European Journal of Clinical Pharmacology 22: 459–462, 1982PubMedCrossRefGoogle Scholar
  5. Artini D, Abbiati R, Orsini G, Parenti MA, Bloch K, et al. Pharmacodynamic aspects of two sulphonylurea derivatives: glipizide and glibenclamide. Diabetologia 9 (Suppl.): 311–316, 1973CrossRefGoogle Scholar
  6. Asmal AC, Marble A. Oral hypoglycaemic agents: an update. Drugs 28: 62–78, 1984PubMedCrossRefGoogle Scholar
  7. Asplund K, Wiholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report of 57 cases. Diabetologia 24: 412–417, 1983PubMedCrossRefGoogle Scholar
  8. Axelgaard G, Skensved H, Asfeldt VH. Hypoglykaemi ved behandling med sulfonylurinstoffer. Ugeskrift for Laeger 148: 2155–2158, 1986PubMedGoogle Scholar
  9. Balant L, Fabre J, Zahnd GR. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. European Journal of Clinical Pharmacology 8: 63–69, 1975PubMedCrossRefGoogle Scholar
  10. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency, diabetologia 9 (Suppl.): 331–338, 1973CrossRefGoogle Scholar
  11. Balant L, Zahnd GR, Weber F, Fabre J. Behaviour of glibenclamide on repeated administration to diabetic patients. European Journal of Clinical Pharmacology 11: 19–25, 1977PubMedCrossRefGoogle Scholar
  12. Balant L. Les sulfonylurees hypoglycemiantes: un probleme de generations? Considerations pharmacocinetiques et pharmacodynamiques. Diabete et Metabolisme 4: 135–143, 1978PubMedGoogle Scholar
  13. Balant L, Fabre J, Loutan L, Samini H. Does 4-hydroxyglibenclamide show hypoglycaemic activity? Arzneimittel Forschung 29: 162–163, 1979PubMedGoogle Scholar
  14. Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clinical Pharmacokinetics 6: 215–241, 1981PubMedCrossRefGoogle Scholar
  15. Barnes AJ, Garbien KJT, Crowley MF, Bloom A. Effects of short and long term chlorpropamide treatment on insulin release and blood glucose. Lancet 2: 69–72, 1974PubMedCrossRefGoogle Scholar
  16. Barnett AH, Eff C, Leslie RDG, Pyke DA. Diabetes in identical twins: a study of 200 pairs. Diabetologia 20: 87–93, 1981PubMedCrossRefGoogle Scholar
  17. Benakis A, Glasson B. Metabolic study of 14C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes. In Keen et al. (Eds) Gliclazide and the treatment of diabetes, International Congress and Symposium Series No. 20, pp. 57–69, Academic Press and Royal Society of Medicine, London, 1980Google Scholar
  18. Berger W, Cardiff F, Pasquel M, Rump A. Die relative Haufigkeit der Schweren Sulfonylharnstoff-Hypoglykamie in den letzten 25 Jahren in der Schweiz. Schweizerische Medizinische Wochenschrift 116: 145–151, 1986PubMedGoogle Scholar
  19. Bergman U, Boman G, Wiholm B-E. Epidemiology of adverse drug reactions to phenformin and metformin. British Medical Journal 2: 464–466, 1978PubMedCrossRefGoogle Scholar
  20. Bergman U, Christenson I, Jansson B, Wiholm B-E, Ostman J. Wide variation in serum chlorpropamide concentration in outpatients. European Journal of Clinical Pharmacology 18: 165–169, 1980PubMedCrossRefGoogle Scholar
  21. Blohme G, Waidenstrom J. Glibenclamide and glipizide in maturity onset diabetes. Acta Medica Scandinavica 206: 263–267, 1979PubMedCrossRefGoogle Scholar
  22. Borthwick LJ, Phillips WS. Blood sugar control on a long and short-acting sulphonylurea: glibenclamide versus gliquidone. Abstract. Diabetologia 21: 504–505, 1981Google Scholar
  23. Brockmeir D, Grigoleit H-G, Leonhardt H. Absorption of glibenclamide from different sites of the gastrointestinal tract. European Journal of Clinical Pharmacology 29: 193–197, 1985CrossRefGoogle Scholar
  24. Brogard JM, Pinget M, Dorner M. Effect of middle term gliclazide treatment on insulin secretion in non-insulin-dependent diabetics. Current Medical Research and Opinion 9: 56–63, 1984PubMedCrossRefGoogle Scholar
  25. Brogden RN, Heel RC, Pakes GE, Speight TH, Avery GS. Glipizide: a review of its pharmacological properties and therapeutic use. Drugs 18: 329–353, 1979PubMedCrossRefGoogle Scholar
  26. Campbell DB, Adriaenssens P, Hopkins YW, Gordon B, Williams JRB. Pharmacokinetics and metabolism of gliclazide: a review. In Keen et al. (Eds) Gliclazide and the treatment of diabetes, International Congress and Symposium Series No. 20, pp. 71–82, Academic Press, London, 1980Google Scholar
  27. Campbell DB, Gordon BH, Ings RMJ, Beaufils M, Meynier A, et al. The effect of renal disease on the pharmacokinetics of gliclazide in diabetic patients. British Journal of Clinical Pharmacology 21: 572P, 1986Google Scholar
  28. Campbell IW. Metformin and the sulphonylureas: comparative risks. Hormone and Metabolic Research 15 (Suppl.): 105–111, 1985Google Scholar
  29. Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. Journal of Clinical Pharmacology 26: 372–377, 1986PubMedGoogle Scholar
  30. Cerasi E, Efendic S, Thornqvist C, Luft R. Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects. Acta Endocrinologica 91: 282–293, 1979PubMedGoogle Scholar
  31. Chaplin S. Genetically determined differences in susceptibility to adverse drug reactions. Adverse Drug Reactions and Acute Poisoning Reviews 4: 211–236, 1984Google Scholar
  32. Clark BF, Campbell IW. Long-term comparative trial of glibenclamide and chlorpropamide in patients with Type II diabetes. Lancet 1: 246–248, 1975CrossRefGoogle Scholar
  33. Craig JW, Miller M, Mills FD. Comparison of the acute hypoglycaemic potencies of tolbutamide and chlorpropamide. Journal of the American Medical Association 172: 779–782, 1960PubMedCrossRefGoogle Scholar
  34. Craig JW, Miller M, Mills FD, Nickerson N. A comparison of the acute hypoglycaemic potencies of tolbutamide and chlorpropamide. Annals of the New York Academy of Sciences 74: 618–620, 1959PubMedCrossRefGoogle Scholar
  35. Crooks MJ, Brown KF. Interaction of glipizide with human serum albumin. Biochemical Pharmacology 24: 298–299, 1975PubMedCrossRefGoogle Scholar
  36. Davidson JK. Glipizide versus tolbutamide: safety and efficacy. In Glipizide — a worldwide review, pp. 179–185, Excerpta medica, Amsterdam, 1984Google Scholar
  37. Davidson M, Lewis AAG, de Mowbray RR, Boucher BJ, Oakley NW, et al. Metabolic and clinical effects of glibenclamide. Lancet 1: 57–61, 1970PubMedCrossRefGoogle Scholar
  38. DeFronzo RA, Ferrannini E. The pathogenesis of non-insulin-dependent diabetes. Medicine 61: 125–140, 1982PubMedCrossRefGoogle Scholar
  39. Diengott D, Mirsky IA. Relation to quantity of sulfonylurea by mouth to the hypoglycaemic response in normal subjects. Journal of Pharmacology and Experimental Therapeutics 118: 168–173, 1956PubMedGoogle Scholar
  40. Doar JWH, Thompson ME, Wilde CE, Sewell PFJ. Influence of treatment with diet alone on oral glucose tolerance test and plasma sugar and insulin levels in patients with maturity-onset diabetes-mellitus. Lancet 1: 1263–1266, 1975PubMedCrossRefGoogle Scholar
  41. Dulin WE, Oster HL, McMahon FG. A new high potency antidiabetic sulfonylurea [N-(1-hexahydro-1-azephenyl)-N′-p-to-lyl-sulfonylurea]. Proceedings of the Society for Experimental Biology and Medicine 107: 245–248, 1961PubMedGoogle Scholar
  42. Editorial. Today’s drugs: glymidine. British Medical Journal 2: 817, 1967Google Scholar
  43. Feldman JM, Lebovitz HE. Endocrine and metabolic effects of glibenclamide. Diabetes 20: 745–755, 1971Google Scholar
  44. Ferner RE, Alberti KGMM. Why is there still disagreement over insulin secretion in non-insulin-dependent diabetes mellitus? Diabetic Medicine 3: 13–17, 1986PubMedCrossRefGoogle Scholar
  45. Ferner RE, Alberti KGMM, Rawlins MD. A glucose clamp technique demonstrates increased B-cell glucose sensitivity after chronic tolbutamide therapy. British Journal of Clinical Pharmacology 20: 270P–271P, 1985Google Scholar
  46. Ferner RE, Alberti KGMM, Rawlins MD. Massive glibenclamide overdose without hypoglycaemia in a man with diabetes after partial pancreatectomy. Human Toxicology 5: 283–284, 1986PubMedCrossRefGoogle Scholar
  47. Ferner RE, Stephenson P, Alberti KGMM. Improved β-cell response correlates with reduced fasting blood glucose in noninsulin-dependent diabetes. Diabetic Medicine, in press, 1987Google Scholar
  48. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action with non-insulin-dependent diabetes mellitus. New England Journal of Medicine 314: 1280–1286, 1986PubMedCrossRefGoogle Scholar
  49. Forette B, Rolland A, Hopkins Y, Gordon B, Campbell B. Gliclazide kinetics in the elderly. In Alberti et al. (Eds) 11th Congress of the International Diabetes Foundation, p. 9, Excerpta Medica, Amsterdam, 1982Google Scholar
  50. Frederiksen PK, Mogensen EF. A clinical comparison between glipizide and glibenclamide in the treatment of maturity onset diabetes: a controlled double-blind study cross-over study. Current Therapeutic Research 32: 1–7, 1982Google Scholar
  51. Frey HMM, Rosenlund B. Studies in patients with chlorpropamide-induced hypoglycemia. Diabetes 19: 930–937, 1970PubMedGoogle Scholar
  52. Fuller JH. Clinical trials in diabetes mellitus. In Mann et al. (Eds) Diabetes in epidemiological perspective, pp. 265–285, Churchill Livingstone, Edinburgh, 1983Google Scholar
  53. Fuszganger RD, Goberna R, Hinz M, Jaros P, Karsten C, et al. Comparative studies on the dynamics of insulin secretion following HB419 and tolbutamide of the perfused isolated rat pancreas and the perfused pieces and islets of rat pancreas. Hormone and Metabolic Research 1 (Suppl.): 34–40, 1969Google Scholar
  54. Galloway JA, McMahon RE, Culp HW, Marshall FJ, Young EC. Metabolism, blood levels and rate of excretion of acetohexamide in human subjects. Diabetes 16: 118–127, 1967PubMedGoogle Scholar
  55. Gerich JE. Sulfonylureas in the treatment of diabetes mellitus — 1985. Mayo Clinic Proceedings 60: 439–443, 1985PubMedGoogle Scholar
  56. Ginier P, Madan S, Fajardo F, Leven SR. Once daily use of glyburide. American Journal of Medicine 79 (Suppl. B): 72–77, 1985PubMedCrossRefGoogle Scholar
  57. Goldner MG (Ed.). Chlorpropamide and diabetes mellitus. Annals of the New York Academy of Sciences 74(3): 407–1028, 1959Google Scholar
  58. Greenfield MS, Doberne L, Rosenthal M, Schulz B, Widstrom A, et al. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin dependent diabetes mellitus. Diabetes 31: 307–312, 1982PubMedCrossRefGoogle Scholar
  59. Groop L, Wahlin-Boll E, Groop P-H, Totterman K-J, Melander A, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in Type 2 diabetics. European Journal of Clinical Pharmacology 28: 697–704, 1985PubMedCrossRefGoogle Scholar
  60. Guirgis FK, Ghanen MH, Abdel-Hey MM. Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents. Arzneimittel Forschung 26: 435–437, 1976PubMedGoogle Scholar
  61. Gylfe E, Hellman B, Sehlin J, Taljedal IB. Interaction of sulfonylurea with the pancreatic B-cell. Experientia 40: 1126–1134, 1984PubMedCrossRefGoogle Scholar
  62. Haupt E, Koberich W, Beyer J, Schoffling K. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide: 1; dose response relations and repeated administration in diabetic subjects. Diabetologia 7: 449–454, 1971aPubMedCrossRefGoogle Scholar
  63. Haupt E, Koberich W, Beyer J, Schoffling K. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. 2. Repeated administration in combination with glucose. Diabetologia 7: 455–460, 1971bPubMedCrossRefGoogle Scholar
  64. Haupt E, Kullmer KA, Schoffling K. Pharmacodynamics of Glurenorm. Diabetologia Croatica 5: 373–391, 1976Google Scholar
  65. Haupt E, Putschky F, Zoltobrocki M, Schoffling K. Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in Type 2 diabetes: intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420). Deutsche Medizinische Wochenschrift 109: 210–213, 1984PubMedCrossRefGoogle Scholar
  66. Hecht A, Gershberg H, Hulse M. Effect of chlorpropamide treatment on insulin in diabetics: its relationship with the hypoglycaemic effect. Metabolism 22: 723–733, 1973PubMedCrossRefGoogle Scholar
  67. Heine P, Kewitz H, Schnapperelle U. Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus. European Journal of Clinical Pharmacology 7: 321–330, 1974PubMedCrossRefGoogle Scholar
  68. Hellman B, Sehlin J, Taljedal I-B. Glibenclamide is exceptional among hypoglycaemic agents in accumulating progressively in B-cell rich pancreatic islets. Acta Endocrinologica 105: 385–390, 1984PubMedGoogle Scholar
  69. Herchuelz A, Malaisse W. Insulinotropic potency of glipizide in vitro. Diabetologia 9 (Suppl.): 309–310, 1973CrossRefGoogle Scholar
  70. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete et Metabolisme 5: 233–245, 1979PubMedGoogle Scholar
  71. Hermansen K. Tolbutamide, glucose, calcium and somatostatin secretion. Acta Endocrinologica 99: 86–93, 1982PubMedGoogle Scholar
  72. Holmes B, Heel RC, Brogden RN, Speight TM, Avery GS. Gliclazide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 27: 301–327, 1984PubMedCrossRefGoogle Scholar
  73. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC. Sulphonylurea therapy doubles B-cell response to glucose in Type 2 diabetics. Diabetologia 28: 809–814, 1985PubMedCrossRefGoogle Scholar
  74. Howell SL, Lacy PE. Studies of the effect of HB419 (glibenclamide) on isolated islets and granules. Hormone and Metabolic Research 1 (Suppl.): 45–47, 1969CrossRefGoogle Scholar
  75. Hughes TA, Kramer JO, Segrest JP. Effects of glyburide therapy on lipoproteins in non-insulin dependent diabetes mellitus. American Journal of Medicine 79 (Suppl. B): 86–91, 1985PubMedCrossRefGoogle Scholar
  76. Hurwitz D, McCuistion AC. Tolbutamide: a double-blind study of its effects in patients. New England Journal of Medicine 257: 931–933, 1957PubMedCrossRefGoogle Scholar
  77. Huupponen R, Viikari J, Saarimaa H. Chlorpropamide and glibenclamide serum concentrations in hospitalised patients. Annals of Clinical Research 14: 119–122, 1982PubMedGoogle Scholar
  78. Ings RMJ, Lawrence JR, McDonald A, McEwan J, Pidgen AW, et al. Glibenclamide pharmacokinetics in healthy volunteers: evidence for zero-order drug absorption. British Journal of Clinical Pharmacology 13: 264P–265P, 1982Google Scholar
  79. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents, part one. Drugs 22: 211–245, 1981aPubMedCrossRefGoogle Scholar
  80. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents, part two. Drugs 22: 295–320, 1981bPubMedCrossRefGoogle Scholar
  81. Jankowski A, Wichlinski LM, Bokowski W, Romanski B. Correlation between serum concentration and hypoglycaemic effect of chlorpropamide in man. Polish Journal of Pharmacology and Pharmacy 36: 449–453, 1984PubMedGoogle Scholar
  82. Jerntorp P, Aimer L-O, Ohlin H, Wahlin-Boll E, Melander A. Plasma chlorpropamide: a critical factor in chlorpropamidealcohol flush. European Journal of Clinical Pharmacology 24: 237–242, 1983PubMedCrossRefGoogle Scholar
  83. Johansen K, Orskov H. The stimulating effect on insulin secretion in long-term tolbutamide treatment. Acta Endocrinologica 71: 709–715, 1972PubMedGoogle Scholar
  84. Johnson SF, Schade DS, Peake GT. Chlorpropamide-induced hypoglycaemia: successful treatment with diazoxide. American Journal of Medicine 63: 799–804, 1977PubMedCrossRefGoogle Scholar
  85. Joost HG, Arend W, Holze SA. Effects of tolbutamide on insulin binding to isolated fat cells of the rat. Biochemical Pharmacology 31: 1227–1231, 1982PubMedCrossRefGoogle Scholar
  86. Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, et al. Chronic chlorpropamide therapy of non-insulin dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. Journal of Endocrinology and Metabolism 55: 321–328, 1982CrossRefGoogle Scholar
  87. Karam JH, Matin SB, Forsham PH. Antidiabetic drugs after the University Group Diabetes Program. Annual Review of Pharmacology 15: 351–366, 1975PubMedCrossRefGoogle Scholar
  88. Katz HM, Bissei G. Blood sugar lowering effects of chlorpropamide and tolbutamide. A double-blind co-operative study. Diabetes 14: 650–657, 1965PubMedGoogle Scholar
  89. Kawashima K, Kuzuya T, Matsuda A. Radioimmunoassay of glibenclamide. Diabetes 28: 221–226, 1979PubMedCrossRefGoogle Scholar
  90. Knauf RE, Fajans SS, Ramirez E, Conn JW. Metabolic studies of chlorpropamide in normal man and in diabetic subjects. Annals of the New York Academy of Sciences 74: 603–617, 1959CrossRefGoogle Scholar
  91. Kobayashi K, Kimura M, Sakoguchi T, Kitani Y, Mitsuo H, et al. Influence of blood proteins on biomedical analysis. III: pharmacokinetics and protein binding of gliclazide. Journal of Pharmacobio-Dynamics 4: 436–442, 1981PubMedCrossRefGoogle Scholar
  92. Kolterman OG. Longitudinal evaluation of the effects of sulphonylurea therapy in subjects with Type 2 diabetes mellitus. American Journal of Medicine 7 (Suppl. B): 23–33, 1985CrossRefGoogle Scholar
  93. Kopitar Z. Humanpharmakokinetik und Metabolismus von 14C-markiertem Gliquidone (AR-DF26). Arzneimittel Forschung 25: 1455–1460, 1975PubMedGoogle Scholar
  94. Kopitar Z, Koss FW. Pharmacokinetic behaviour of ARDF 26, a new sulphonylurea. Proceedings of the International Conference on Glurenorm, 13–14th March, pp. 20–29, 1975Google Scholar
  95. Lebovitz HE. Glipizidc: a second-generation sulphonylurea hypoglycaemic agent. Pharmacotherapy 5: 63–77, 1985PubMedGoogle Scholar
  96. Loffler G, Trautschold I, Schweitzer T, Lohmann E. Effects of glibenclamide and tolbutamide on isolated pancreatic islets of the rat. Hormone and Metabolic Research 1 (Suppl.): 41–44, 1969CrossRefGoogle Scholar
  97. MacWalter RS, el Debani AH, Feely J, Stevenson IH. Potentiation by ranitidine of the hypoglycaemic response to glipizide in diabetic patients. British Journal of Clinical Pharmacology 19: 121P–122P, 1985Google Scholar
  98. Malaisse WJ. Stimulus-secretion coupling in the pancreatic B-cell: concluding remarks. Experientia 40: 1134–1135, 1984PubMedCrossRefGoogle Scholar
  99. Malaisse WJ, Couturier E, Valverde I. The insulinotropic action of gliclazide: possible mode of action: pharmacokinetics and metabolism of gliclazide: a review. In Keen H et al. (Eds) Gliclazide and the treatment of diabetes, International Congress and Symposium Series No. 20, pp. 37–42, Academic Press and Royal Society of Medicine, London, 1980Google Scholar
  100. Martin BJ, Kesson CM. Dietary control of elderly diabetic patients — a case for review. Practical Diabetes 3: 146–148, 1986CrossRefGoogle Scholar
  101. Martin DB. Type 2 diabetes: Insulin versus oral agents. New England Journal of Medicine 314: 1314–1315, 1986PubMedCrossRefGoogle Scholar
  102. Matsuda A, Kuzuya T, Sugita Y, Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Hormone and Metabolic Research 15: 425–428, 1983PubMedCrossRefGoogle Scholar
  103. Matthews EK, Shotton PA. The control of 86Rb efflux from rat isolated pancreatic islets by the sulphonylureas tolbutamide and glibenclamide. British Journal of Pharmacology 82: 689–700, 1984PubMedCrossRefGoogle Scholar
  104. McMahon FG, Upjohn HL, Carpenter OS, Wright JB, Oster HL, et al. The comparative pharmacology of a variety of hypoglycaemic drugs. Current Therapeutic Research 4: 330–343, 1962Google Scholar
  105. Melander A, Sartor G, Wahlin-Boll E, Schersten B, Bitzen PO. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. British Medical Journal 1: 142–144, 1978PubMedCrossRefGoogle Scholar
  106. Miyazaki H, Fujii T, Yoshida K, Arakawa S, Furukawa H, et al. Disposition and metabolism of [3H] gliclazide in rats. European Journal of Drug Metabolism and Pharmacokinetics 8: 117–131, 1983CrossRefGoogle Scholar
  107. Monro AM, Welling PG. The bioavailability in man of marketed brands of chlorpropamide. European Journal of Clinical Pharmacology 7: 47–49, 1974PubMedCrossRefGoogle Scholar
  108. Moorhouse JA. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects. Canadian Medical Association Journal 96: 536–539, 1967PubMedGoogle Scholar
  109. Multicentre Study. UK prospective study of therapies of maturity-onset diabetes. Diabetologia 24: 404–411, 1983Google Scholar
  110. Neuvonen PJ, Kannisto H, Hirvisalo EL. Effect of activated charcoal on absorption of tolbutamide and valproate in man. European Journal of Clinical Pharmacology 24: 243–246, 1983PubMedCrossRefGoogle Scholar
  111. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate and ammonium chloride on chlorpropamide kinetics. Clinical Pharmacology and Therapeutics 33: 386–393, 1983PubMedCrossRefGoogle Scholar
  112. Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation. Lancet 1: 837–838, 1981PubMedCrossRefGoogle Scholar
  113. Oates NS, Shah RR, Idle JR, Smith RL. Genetic polymorphism of phenformin 4-hydroxylation. Clinical Pharmacology and Therapeutics 32: 81–89, 1982PubMedCrossRefGoogle Scholar
  114. Okumura K, Arakawa M, Hori R. Tissue distribution and metabolism of drugs VI: effect of second drugs on pancreatic distribution and insulin-releasing activity of sulphonylureas in perfused rat pancreas. Journal of Pharmaceutical Sciences 69: 157–159, 1980PubMedCrossRefGoogle Scholar
  115. Olson SC, Ayres JW, Antal EJ, Albert KS. Effect of food and tablet age on relative bioavailability and pharmacodynamics of two tolbutamide products. Journal of Pharmaceutical Sciences 74: 735–739, 1985PubMedCrossRefGoogle Scholar
  116. Ostenson C-G, Grill V, Nylen A, Efendic S. Modulation by IBMX, fasting and experimental diabetes of glibenclamide-induced islet hormone release from the perfused rat pancreas. Diabete et Metabolisme 9: 58–65, 1983PubMedGoogle Scholar
  117. Ostman J, Christenson I, Jansson B, Weiner L. The antidiabetic effect and pharmacokinetic properties of glipizide. Acta Medica Scandinavica 210: 173–180, 1981PubMedCrossRefGoogle Scholar
  118. O’Sullivan DJ, Cashman WF. Blood glucose variations and clinical experience with glibenclamide in diabetes mellitus. British Medical Journal 2: 572–574, 1970PubMedCrossRefGoogle Scholar
  119. Otto H, Halle V, Thun G. Changes of serum insulin in healthy subjects after intravenous and peroral application of glibenclamide HB419. Hormone and Metabolic Research 1 (Suppl.): 81–84, 1969Google Scholar
  120. Pearson JG, Antal EJ, Raehl CL, Gosch HK, Craig WA, et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying degrees of renal function. Clinical Pharmacology and Therapeutics 39: 318–324, 1986PubMedCrossRefGoogle Scholar
  121. Pfeifer MA, Graf RJ, Halter JB, Porte D. The regulation of glucose-induced insulin secretion by prestimulus glucose level and tolbutamide in normal man. Diabetologia 21: 198–205, 1981aPubMedCrossRefGoogle Scholar
  122. Pfeifer MA, Halter JB, Beard JC, Porte D. Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 53: 1256–1262, 1981bPubMedCrossRefGoogle Scholar
  123. Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clinical Pharmacology and Therapeutics 22: 573–579, 1977PubMedGoogle Scholar
  124. Prosser PR, Kosola JW, Bowers CY. The 24-hour effects of glyburide and chlorpropamide after chronic treatment of Type 2 diabetic patients. American Journal of Medical Science 289: 179–185, 1985CrossRefGoogle Scholar
  125. Radding RS, Kern LR, Owens JC. Comparative pharmacology of the sulfonylureas. Metabolism 11: 411–415, 1962PubMedGoogle Scholar
  126. Rogers HJ, Spector RG, Morrison PJ, Bradbrook ID. Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid Chromatographic assay. Diabetologia 23: 37–40, 1982PubMedCrossRefGoogle Scholar
  127. Rupp W von, Christ O, Fulberth W. Untersuchungen zur Bioavailability von Glibenclamid. Arzneimittel Forschung 22: 471–473, 1972PubMedGoogle Scholar
  128. Samanta A, Jones GR, Burden AC, Shakir I. Improved effect of tolbutamide when given before food in patients on long-term therapy. British Journal of Clinical Pharmacology 18: 647–648, 1984PubMedCrossRefGoogle Scholar
  129. Sartor G, Lundquist I, Melander A, Schersten B, Wahlin-Boll E. Improved effect of glibenclamide on administration before breakfast. European Journal of Clinical Pharmacoldogy 21: 403–408, 1982CrossRefGoogle Scholar
  130. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Influence of food and age on the single-dose kinetics and effects of tolbdutasmide and chlorpropamide. European Journal of Clinical Pharmacology 17: 285–293, 1980aPubMedCrossRefGoogle Scholar
  131. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers. Acta Medica Scandinavica 208: 301–307, 1980bPubMedCrossRefGoogle Scholar
  132. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 18: 17–22, 1980cPubMedCrossRefGoogle Scholar
  133. Sartor G, Schersten B, Melander A. Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetics. Acta Medica Scandinavica 203: 211–214, 1978PubMedCrossRefGoogle Scholar
  134. Schmidt HAE, Schoog M, Schweer KH, Winkler E. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered 14C-glipizide, a new antidiabetic. Diabetologia 9 (Suppl.): 320–330, 1973CrossRefGoogle Scholar
  135. Scott J, Poffenbarger PL. Pharmacodynamics of tolbutamide metabolism in humans. Diabetes 28: 41–51, 1979PubMedCrossRefGoogle Scholar
  136. Seltzer HS. Drug-induced hypoglycaemia: a review based on 473 cases. Diabetes 21: 955–966, 1972PubMedGoogle Scholar
  137. Seltzer HS, Allen EW, Brennan MT. Failure of prolonged sulphonylurea administration to enhance insulinotropic response to glycaemic stimulus. Diabetes 14: 392–395, 1965PubMedGoogle Scholar
  138. Servier Laboratories. Gliclazide information booklet. Servier Laboratories, Slough, 1984Google Scholar
  139. Sheldon J, Anderson J, Stoner L. Serum concentration and urinary excretion of oral sulfonylurea compounds. Relation to diabetic control. Diabetes 14: 362–367, 1965PubMedGoogle Scholar
  140. Sheldon J, Taylor KW, Anderson J. The effects of long-term acetohexamide treatment on pancreatic islet cell function in maturity-onset diabetes. Metabolism 15: 874–883, 1966PubMedCrossRefGoogle Scholar
  141. Shen SW, Bressler R. Clinical pharmacology of oral anti-diabetic agents. New England Journal of Medicine 296: 493–496 and 787-793, 1977PubMedCrossRefGoogle Scholar
  142. Shenfield GM, Logan A, Shirling D, Baird J. Plasma insulin, glucose and lipids in maturity onset diabetes treated with chlorpropamide. Diabetologia 13: 367–371, 1977PubMedCrossRefGoogle Scholar
  143. Shinn AF, Shrewsbury RP. Evaluation of drug interactions, CV Mosby, St Louis, 1985Google Scholar
  144. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clinical Pharmacology and Therapeutics 24: 683–693, 1978PubMedGoogle Scholar
  145. Smith DL, Vecchio TJ, Forist AA. Metabolism of antidiabetic sulphonylureas in man. 1. Biological half-lives of the p-acetylbenzenesulfonylureas, U-18536 and acetohexamide and their metabolites. Metabolism 14: 229–240, 1965PubMedCrossRefGoogle Scholar
  146. Sonksen PK, Lowy C, Perkins JR, West TET. Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone. Diabetologia 20: 22–30, 1981PubMedCrossRefGoogle Scholar
  147. Stephen F, Reville P, Laharpe F de, Doerflinger M-A. Action of gliclazide on the insulinogenic index during short and long term treatment of diabetes mellitus. In Keen H et al. (Eds) Gliclazide and the treatment of diabetes, International Congress and Symposium Series No. 20, pp. 91–98, Academic Press and Royal Society of Medicine, London, 1980Google Scholar
  148. Stewart RDH, Anderson DE. Glycodiazine in diabetes mellitus: a clinical trial. British Medical Journal 2: 682–684, 1965PubMedCrossRefGoogle Scholar
  149. Strata A, Magnati G, Pugnoli C. Studies on the clinical pharmacology and therapeutics of gliclazide: Pharmacokinetics and metabolism of gliclazide: a review. In Keen et al. (Eds), Gliclazide and the treatment of diabetes, International Congress and Symposium Series No. 20, pp. 103–111, Academic Press and Royal Society of Medicine, London, 1980Google Scholar
  150. Sturgess NC, Ashford MLJ, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 2: 474–475, 1985PubMedCrossRefGoogle Scholar
  151. Tamassia V. Pharmacokinetics and bioavailability of glipizide. Current Medical Research and Opinion 3 (Suppl. 1): 20–30, 1975CrossRefGoogle Scholar
  152. Taylor JA. Pharmacokinetics and biotransformation of chlorpropamide in man. Clinical Pharmacology and Therapeutics 13: 710–718, 1972PubMedGoogle Scholar
  153. Taylor R, Isles TE, MacLaren S, Stevenson IH, Newton RW. Comparison of metabolic profiles in non-obese non-insulin-dependent diabetics receiving glipzide and glibenclamide. Diabetologia Croatica 12: 279–292, 1983Google Scholar
  154. Taylor T, Assinder DF, Chasseand LF, Bradford PM, Burton JS. Plasma concentrations, bioavailability and dissolution of chlorpropamide. European Journal of Clinical Pharmacology 11: 207–212, 1977PubMedCrossRefGoogle Scholar
  155. Tchobroutsky G. Metabolic control and diabetic complications. In Brownlee (Ed.) Handbook of diabetes mellitus, Vol. 5, Comment and future therapies, pp. 3–39, Garland STMP Press, New York, 1981Google Scholar
  156. Thomas RC, Duchamp DJ, Judy RW, Ikeda GJ. Metabolic fate of tolazamide in man and in the rat. Journal of Medicinal Chemistry 21: 725–732, 1978PubMedCrossRefGoogle Scholar
  157. Tsuchiya S, Sakurai T, Sekiguch S-I. Non-enzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylureas. Biochemical Pharmacology 33: 2967–2971, 1984PubMedCrossRefGoogle Scholar
  158. Uihlein M, Sistovaris N. High performance liquid column and thin layer Chromatographic determination of human serum glibenclamide at therapeutic levels. Journal of Chromatography 227: 93–101, 1982PubMedCrossRefGoogle Scholar
  159. Volk BW, Lazarus SS. β Cell hypersecretion after long term sulfonylurea treatment. Acta Pathologica 78: 115–126, 1964Google Scholar
  160. Wahlin-Boll E. Kinetics-effect relations of glipizide. Doctoral Thesis, University of Lund, Dalby, Sweden, 1986Google Scholar
  161. Wahlin-Boll E, Aimer L-O, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in Type 2 diabetics. Clinical Pharmacokinetics 7: 363–372, 1982bPubMedCrossRefGoogle Scholar
  162. Wahlin-Boll E, Melander A, Sartor G, Schersten B. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. European Journal of Clinical Pharmacology 18: 279–283, 1980PubMedCrossRefGoogle Scholar
  163. Wahlin-Boll E, Sartor G, Melander A, Schersten B. Impaired effect of sulphonylurea following increased dosage. European Journal of Clinical Pharmacology 22: 21–25, 1982aPubMedCrossRefGoogle Scholar
  164. Wajchenberg BL, Nery M, Lerne CE, Silveira AA, Fioratti P, et al. Effect of prolonged gliclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity onset diabetes. Clinical Pharmacology and Therapeutics 27: 375–378, 1980PubMedCrossRefGoogle Scholar
  165. Ward EA, Lang DA, Philipps MR, Turner RC. Comparison of chlorpropamide and glibenclamide treatment of maturity onset diabetes: control assessed by fasting glucose concentrations. Diabetes Care 4: 293–295, 1981PubMedCrossRefGoogle Scholar
  166. Weller C, Donesa A, Linder M. Evaluation of duration of action and clinical effectiveness of acetohexamide. Metabolism 11: 551–555, 1962PubMedGoogle Scholar
  167. Welling PG, Patel RB, Patel UR, Gillespie WR, Craig WA, et al. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. Journal of Pharmaceutical Science 71: 1259–1263, 1982CrossRefGoogle Scholar
  168. West KM, McCampbell SR. Relative potencies of chlorpropamide and tolbutamide in man. Annals of the New York Academy of Sciences 74: 473–477, 1959PubMedCrossRefGoogle Scholar
  169. Wiholm BE. Irregular drug intake and serum chlorpropamide concentrations. European Journal of Clinical Pharmacology 18: 159–163, 1980CrossRefGoogle Scholar
  170. Wiles PG, Pyke DA. The chlorpropamide-alcohol flush. Clinical Science 67: 375–381, 1984PubMedGoogle Scholar
  171. Winthrop Laboratories Ltd. Glurenorm: product information booklet, Winthrop Laboratories Ltd, Guildford, 1985Google Scholar
  172. Wright CE, Antal EJ. The influence of age on the pharmacokinetics of tolazamide. Abstract. Drug Intelligence and Clinical Pharmacy 19: 458, 1985Google Scholar
  173. Zuber MX, Wang S-M, Thammavaran KV, Reed DK, Reed BC. Elevation of the number of cell-surface insulin receptors and the rate of 2-deoxyglucose uptake by exposure of 3T3-Li adipocytes to tolbutamide. Journal of Biological Chemistry 260: 14045–14052, 1985PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • Robin E. Ferner
    • 1
  • Stephen Chaplin
    • 1
  1. 1.Northern Regional Drug Information Unit, Wolfson Unit of Clinical PharmacologyUniversity of Newcastle upon Tyne, Royal Victoria InfirmaryNewcastle upon TyneEngland

Personalised recommendations